{"transactions":[{"id":912082,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-10T13:00:15.000Z","date":"2026-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":36687,"price":6.52,"value":239199.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"125,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6603336,"source":{"system":"sec-edgar","filing":"0001171843-26-000722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000722/ownership.xml","form_type":"4"}},{"id":941059,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-01-12T13:00:13.000Z","date":"2026-01-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":46777,"price":5.35,"value":250256.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 318,750 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6640023,"source":{"system":"sec-edgar","filing":"0001171843-26-000205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000205/ownership.xml","form_type":"4"}},{"id":951654,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:33:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 2, 2026."}],"balance_after":2000000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001171843-26-000060","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000060/ownership.xml","form_type":"4"}},{"id":951653,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:33:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":5.17,"value":1292500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027."}],"balance_after":6686800,"source":{"system":"sec-edgar","filing":"0001171843-26-000060","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000060/ownership.xml","form_type":"4"}},{"id":995846,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-11-18T13:30:51.000Z","date":"2025-11-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":44025,"price":4.83,"value":212640.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"250,000 of the shares represent unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6436800,"source":{"system":"sec-edgar","filing":"0001171843-25-007400","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325007400/ownership.xml","form_type":"4"}},{"id":1133470,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-05-27T19:24:21.000Z","date":"2025-05-27","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.11,"value":21100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in two transactions at prices of $2.105 and $2.115 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6480825,"source":{"system":"sec-edgar","filing":"0001171843-25-003462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325003462/ownership.xml","form_type":"4"}},{"id":1269704,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:12:03.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":1500000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"CommonStock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001171843-25-000831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000831/ownership.xml","form_type":"4"}},{"id":1274068,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-11T15:37:49.000Z","date":"2025-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":41687,"price":3.5,"value":145904.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"125,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 250,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6470825,"source":{"system":"sec-edgar","filing":"0001171843-25-000735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000735/ownership.xml","form_type":"4"}},{"id":1304344,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-01-13T13:30:10.000Z","date":"2025-01-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":58054,"price":1.86,"value":107980.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"150,000 of the shares represent unvested RSUs granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 375,000 of the shares represent unvested RSUs granted on February 8, 2023. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested RSUs granted on January 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6512512,"source":{"system":"sec-edgar","filing":"0001171843-25-000195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000195/ownership.xml","form_type":"4"}},{"id":1651650,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT"}}],"security":"Common Stock","published_at":"2024-02-09T17:49:22.000Z","date":"2024-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":44782,"price":1.45,"value":64933.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 16, 2022. 375,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6570566,"source":{"system":"sec-edgar","filing":"0001171843-24-000714","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000714/ownership.xml","form_type":"4"}},{"id":1681640,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-10T15:31:08.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":637500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting February 9, 2024."}],"balance_after":637500,"derivative":{"exercise_price":1.93,"expiration_date":"2034-01-08","underlying":"CommonStock","underlying_shares":637500},"source":{"system":"sec-edgar","filing":"0001171843-24-000178","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000178/ownership.xml","form_type":"4"}},{"id":1681639,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Common Stock","published_at":"2024-01-10T15:31:08.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":637500,"price":1.93,"value":1230375.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on January 9, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"300,000 of the shares represents unvested restricted stock units (\"RSU\") granted on November 16, 2021. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 637,500 of the shares represents unvested restricted stock units (\"RSU\") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025."}],"balance_after":6615348,"source":{"system":"sec-edgar","filing":"0001171843-24-000178","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000178/ownership.xml","form_type":"4"}},{"id":1732765,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-11-21T19:08:42.000Z","date":"2023-11-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":44025,"price":1.5,"value":66037.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"12,222 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5977848,"source":{"system":"sec-edgar","filing":"0001171843-23-007222","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323007222/ownership.xml","form_type":"4"}},{"id":1958876,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-03-10T18:34:51.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":10000,"price":3.37,"value":33700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.30 to $3.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"89,051 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 27,937 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 61,114 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":6021873,"source":{"system":"sec-edgar","filing":"0001171843-23-001588","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323001588/ownership.xml","form_type":"4"}},{"id":1990520,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-27T16:39:07.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":20000,"price":3.98,"value":79600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $3.98 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":6011873,"source":{"system":"sec-edgar","filing":"0001171843-23-001175","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323001175/ownership.xml","form_type":"4"}},{"id":2013679,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-15T15:47:57.000Z","date":"2023-02-15","kind":"purchase","acquired":true,"shares":20000,"price":3.86,"value":77200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.76 to $3.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5991873,"source":{"system":"sec-edgar","filing":"0001171843-23-000974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000974/ownership.xml","form_type":"4"}},{"id":2024820,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:23:48.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":700000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"CommonStock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001171843-23-000851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000851/ownership.xml","form_type":"4"}},{"id":2024819,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-02-09T21:23:48.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on February 8, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"100,751 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 33,525 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 67,226 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. 500,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5971873,"source":{"system":"sec-edgar","filing":"0001171843-23-000851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000851/ownership.xml","form_type":"4"}},{"id":2040398,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-31T15:14:18.000Z","date":"2023-01-31","kind":"purchase","acquired":true,"shares":20000,"price":4.05,"value":81000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5471873,"source":{"system":"sec-edgar","filing":"0001171843-23-000557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000557/ownership.xml","form_type":"4"}},{"id":2047526,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2023-01-24T15:49:22.000Z","date":"2023-01-24","kind":"purchase","acquired":true,"shares":20000,"price":4.19,"value":83800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"112,449 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 39,112 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 73,337 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 450,000 of the shares represents unvested restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022."}],"balance_after":5451873,"source":{"system":"sec-edgar","filing":"0001171843-23-000419","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000419/ownership.xml","form_type":"4"}},{"id":2149974,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-28T20:45:33.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":10000,"price":2.32,"value":23200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.30 to $2.33 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5431873,"source":{"system":"sec-edgar","filing":"0001171843-22-006282","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006282/ownership.xml","form_type":"4"}},{"id":2150557,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-27T13:47:18.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":15000,"price":2.27,"value":34050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.24 to $2.28 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5421873,"source":{"system":"sec-edgar","filing":"0001171843-22-006243","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006243/ownership.xml","form_type":"4"}},{"id":2163178,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-08T14:12:23.000Z","date":"2022-09-07","kind":"purchase","acquired":true,"shares":15000,"price":3.03,"value":45450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $3.02 to $3.04 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5406873,"source":{"system":"sec-edgar","filing":"0001171843-22-006005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322006005/ownership.xml","form_type":"4"}},{"id":2169019,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-09-01T18:37:05.000Z","date":"2022-09-01","kind":"purchase","acquired":true,"shares":15000,"price":2.83,"value":42450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.77 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"159,246 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 61,462 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 97,784 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5391873,"source":{"system":"sec-edgar","filing":"0001171843-22-005905","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005905/ownership.xml","form_type":"4"}},{"id":2181843,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-17T20:06:55.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":15000,"price":3.05,"value":45750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5376873,"source":{"system":"sec-edgar","filing":"0001171843-22-005700","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005700/ownership.xml","form_type":"4"}},{"id":2189557,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-10T14:51:32.000Z","date":"2022-08-10","kind":"purchase","acquired":true,"shares":15000,"price":2.64,"value":39600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.57 to $2.75 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5361873,"source":{"system":"sec-edgar","filing":"0001171843-22-005567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005567/ownership.xml","form_type":"4"}},{"id":2197737,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-08-02T13:15:40.000Z","date":"2022-08-01","kind":"purchase","acquired":true,"shares":15000,"price":2.58,"value":38700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.62 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"170,946 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 67,050 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 103,896 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5346873,"source":{"system":"sec-edgar","filing":"0001171843-22-005231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322005231/ownership.xml","form_type":"4"}},{"id":2225500,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-21T17:41:46.000Z","date":"2022-06-21","kind":"purchase","acquired":true,"shares":20000,"price":2.8,"value":56000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.78 to $2.81 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5331873,"source":{"system":"sec-edgar","filing":"0001171843-22-004440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004440/ownership.xml","form_type":"4"}},{"id":2228018,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-17T20:46:45.000Z","date":"2022-06-16","kind":"purchase","acquired":true,"shares":20000,"price":2.34,"value":46800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.40 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5311873,"source":{"system":"sec-edgar","filing":"0001171843-22-004408","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004408/ownership.xml","form_type":"4"}},{"id":2234232,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-13T19:59:22.000Z","date":"2022-06-13","kind":"purchase","acquired":true,"shares":30000,"price":2.29,"value":68700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.20 to $2.31 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5291873,"source":{"system":"sec-edgar","filing":"0001171843-22-004327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004327/ownership.xml","form_type":"4"}},{"id":2240285,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-07T15:50:59.000Z","date":"2022-06-06","kind":"purchase","acquired":true,"shares":30000,"price":2.83,"value":84900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.82 to $2.87 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5261873,"source":{"system":"sec-edgar","filing":"0001171843-22-004190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004190/ownership.xml","form_type":"4"}},{"id":2249595,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-06-01T16:33:27.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":20000,"price":3.03,"value":60600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.08 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"194,345 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 78,225 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 116,120 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5231873,"source":{"system":"sec-edgar","filing":"0001171843-22-004068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322004068/ownership.xml","form_type":"4"}},{"id":2255325,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-26T18:58:01.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":20000,"price":3.04,"value":60800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.07 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5211873,"source":{"system":"sec-edgar","filing":"0001171843-22-003978","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003978/ownership.xml","form_type":"4"}},{"id":2258395,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-24T12:09:42.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":18355,"price":2.72,"value":49925.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.89 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5191873,"source":{"system":"sec-edgar","filing":"0001171843-22-003899","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003899/ownership.xml","form_type":"4"}},{"id":2268261,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-17T19:17:04.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":20215,"price":2.47,"value":49931.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.50 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5173518,"source":{"system":"sec-edgar","filing":"0001171843-22-003771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003771/ownership.xml","form_type":"4"}},{"id":2276311,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2022-05-10T18:15:10.000Z","date":"2022-05-10","kind":"purchase","acquired":true,"shares":27836,"price":1.8,"value":50104.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.86 per share. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"206,043 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on July 3, 2019, with the remaining 83,812 shares vesting approximately equally per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, with the remaining 122,231 shares vesting approximately equally per month with shares fully vested on December 31, 2023. 600,000 of the shares represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5153303,"source":{"system":"sec-edgar","filing":"0001171843-22-003503","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322003503/ownership.xml","form_type":"4"}},{"id":2378764,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-23T22:30:12.000Z","date":"2022-02-18","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting 03/17/2022."}],"balance_after":700000,"derivative":{"exercise_price":2.4,"expiration_date":"2032-02-17","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0000899243-22-007412","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000089924322007412/doc4a.xml","form_type":"4/A","original_submission_date":"2022-02-18"}},{"id":2385585,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-19T00:13:40.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting 03/17/2022"}],"balance_after":700000,"derivative":{"exercise_price":2.52,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001171843-22-001211","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322001211/ownership.xml","form_type":"4"}},{"id":2504970,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-19T00:00:28.000Z","date":"2021-11-16","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSU\") granted to the reporting person on November 16, 2021. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vesting on November 15, 2022."}],"balance_after":5125467,"source":{"system":"sec-edgar","filing":"0000899243-21-045310","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000089924321045310/doc4.xml","form_type":"4"}},{"id":2826743,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-01T15:35:48.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on February 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":700000,"derivative":{"exercise_price":5,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-21-015099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000120919121015099/doc4.xml","form_type":"4"}},{"id":2933143,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-23T22:00:26.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":250000,"derivative":{"exercise_price":5,"expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-20-065033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000120919120065033/doc4.xml","form_type":"4"}},{"id":3063607,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-11T00:50:28.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of this option is immediately vested and exercisable, with the remainder vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":500000,"derivative":{"exercise_price":5,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-20-021967","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000089924320021967/doc4.xml","form_type":"4"}},{"id":3102075,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-24T01:38:09.000Z","date":"2020-06-19","kind":"purchase","acquired":true,"shares":97431,"price":5,"value":487155.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"586,546 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which vest as follows: restricted stock award granted on February 22, 2018, 3,850.625 shares vest per month with shares fully vested on February 28, 2022, restricted stock award granted on July 3, 2019, 5,587.5 shares vest per month with shares fully vested on July 31, 2023 and restricted stock award granted on December 20, 2019, 25% cliff on December 20, 2020; 6,111.625 shares vest per month thereafter with shares fully vested on December 31, 2023."}],"balance_after":4525467,"source":{"system":"sec-edgar","filing":"0001213900-20-015638","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000121390020015638/ownership.xml","form_type":"4"}},{"id":3310845,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":16200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310844,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310843,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Reflects the correct exercise price of this option.  The exercise price of this option was previously reported as $26.01."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.15,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310842,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.03,"expiration_date":"2026-08-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310841,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":5605,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.1852,"expiration_date":"2025-05-27","underlying":"Common Stock","underlying_shares":5605},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310840,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":18086,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.7804,"expiration_date":"2023-09-25","underlying":"Common Stock","underlying_shares":18086},"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3310839,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-15T13:36:26.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":89695,"price":60,"value":5381700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003435/doc4.xml","form_type":"4"}},{"id":3668145,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T17:27:23.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":16200,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-19-008673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008673/doc4.xml","form_type":"4"}},{"id":3900053,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T17:23:42.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2019 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-036741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118036741/doc4.xml","form_type":"4"}},{"id":4189142,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":67048,"kind":"person","name":"Schuetz Thomas J.","position":1,"cik":"0001591464","reported_name":"Schuetz Thomas J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-10-10T18:06:51.000Z","date":"2017-10-08","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":9000,"derivative":{"exercise_price":26.01,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-056530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117056530/doc4.xml","form_type":"4"}}]}